Summary

RMgm-4190
Malaria parasiteP. berghei
Genotype
DisruptedGene model (rodent): PBANKA_1441700; Gene model (P.falciparum): PF3D7_1226900; Gene product: parasitophorous vacuolar protein 2 (PV2)
Transgene
Transgene not Plasmodium: mCherry/cmyc
Promoter: Gene model: PBANKA_1441700; Gene model (P.falciparum): PF3D7_1226900; Gene product: parasitophorous vacuolar protein 2 (PV2)
3'UTR: Gene model: Not available; Gene product: Not available
Replacement locus: Gene model: PBANKA_1441700; Gene product: parasitophorous vacuolar protein 2 (PV2)
Phenotype Asexual bloodstage;
Last modified: 16 July 2017, 11:10
  *RMgm-4190
Successful modificationThe parasite was generated by the genetic modification
The mutant contains the following genetic modification(s) Gene disruption, Introduction of a transgene
Reference (PubMed-PMID number) Reference 1 (PMID number) : 28691708
MR4 number
Parent parasite used to introduce the genetic modification
Rodent Malaria ParasiteP. berghei
Parent strain/lineP. berghei ANKA
Name parent line/clone Not applicable
Other information parent line
The mutant parasite was generated by
Name PI/ResearcherBatinovic S, Tilley L
Name Group/DepartmentDepartment of Biochemistry and Molecular Biology
Name InstituteBio21 Institute, The University of Melbourne
CityParkville
CountryAustralia
Name of the mutant parasite
RMgm numberRMgm-4190
Principal namePbΔPV2
Alternative name
Standardized name
Is the mutant parasite cloned after genetic modificationYes
Phenotype
Asexual blood stageGrowth and multiplication of blood stages in mice comparable to wild type parasites. Normal virulence.
Gametocyte/GameteNot tested
Fertilization and ookineteNot tested
OocystNot tested
SporozoiteNot tested
Liver stageNot tested
Additional remarks phenotype

Mutant/mutation
The mutant lacks expression of PV2 and expresses mCherry/cmyc under control of the PV2 promoter

Protein (function)
The PV2 protein was identified in P. falciparum by a immunoprecipitation (IP) and mass spectrometry approach using PfEMP1. P. falciparum PV2 was not essential for growth of blood stages in vitro.

Phenotype
Growth and multiplication of blood stages in mice comparable to wild type parasites. Normal virulence (ECM, Experimental Cerebral Malaria)

Additional information

Other mutants


  Disrupted: Mutant parasite with a disrupted gene
Details of the target gene
Gene Model of Rodent Parasite PBANKA_1441700
Gene Model P. falciparum ortholog PF3D7_1226900
Gene productparasitophorous vacuolar protein 2
Gene product: Alternative namePV2
Details of the genetic modification
Inducable system usedNo
Additional remarks inducable system
Type of plasmid/construct used(Linear) plasmid double cross-over
PlasmoGEM (Sanger) construct/vector usedNo
Modified PlasmoGEM construct/vector usedNo
Plasmid/construct map
Plasmid/construct sequence
Restriction sites to linearize plasmid
Partial or complete disruption of the geneComplete
Additional remarks partial/complete disruption
Selectable marker used to select the mutant parasitehdhfr/yfcu
Promoter of the selectable markerpbdhfr
Selection (positive) procedurepyrimethamine
Selection (negative) procedureNo
Additional remarks genetic modification
Additional remarks selection procedure
Primer information: Primers used for amplification of the target sequences  Click to view information
Primer information: Primers used for amplification of the target sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Sequence Primer 3
Additional information primer 3
Sequence Primer 4
Additional information primer 4
Sequence Primer 5
Additional information primer 5
Sequence Primer 6
Additional information primer 6

  Transgene: Mutant parasite expressing a transgene
Type and details of transgene
Is the transgene Plasmodium derived Transgene: not Plasmodium
Transgene namemCherry/cmyc
Details of the genetic modification
Inducable system usedNo
Additional remarks inducable system
Type of plasmid/construct(Linear) plasmid double cross-over
PlasmoGEM (Sanger) construct/vector usedNo
Modified PlasmoGEM construct/vector usedNo
Plasmid/construct map
Plasmid/construct sequence
Restriction sites to linearize plasmid
Selectable marker used to select the mutant parasitehdhfr/yfcu
Promoter of the selectable markerpbdhfr
Selection (positive) procedurepyrimethamine
Selection (negative) procedureNo
Additional remarks genetic modification
Additional remarks selection procedure
Other details transgene
Promoter
Gene Model of Parasite PBANKA_1441700
Gene Model P. falciparum ortholog PF3D7_1226900
Gene productparasitophorous vacuolar protein 2
Gene product: Alternative namePV2
Primer information details of the primers used for amplification of the promoter sequence  Click to view information
Primer information details of the primers used for amplification of the promoter sequence  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
3'-UTR
Gene Model of Parasite Not available
Gene productNot available
Gene product: Alternative name
Primer information details of the primers used for amplification the 3'-UTR sequences  Click to view information
Primer information details of the primers used for amplification the 3'-UTR sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Insertion/Replacement locus
Replacement / InsertionReplacement locus
Gene Model of Parasite PBANKA_1441700
Gene productparasitophorous vacuolar protein 2
Gene product: Alternative namePV2
Primer information details of the primers used for amplification of the target sequences  Click to view information
Primer information details of the primers used for amplification of the target sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Sequence Primer 3
Additional information primer 3
Sequence Primer 4
Additional information primer 4